Genetic Technology (Precision Breeding) Bill

Baroness Parminter Excerpts

Report stage
Wednesday 25th January 2023 Lords Chamber

I say to all of us in this House, because I really feel it, that I certainly support the amendments we have heard about so far. I do not think that they are ideal but they are perhaps the best we can achieve in the time available to us. We must understand that, when we vote, we have a grave responsibility to understand that we could do great harm. The question then is this: what is the good of what we are doing? We are not going to change the feeding of the world’s population with genetically modified crops; actually, that could have been done already had we had the sense to look at how to protect cereals, for example, so many of which are destroyed during storage for all sorts of reasons. One of our responsibilities is to look at how and why these measures are needed. Unfortunately, at the moment, there is a risk that this could be something that is of commercial value for a time but is not necessary for human, planetary, animal or plant value.

[Baroness Parminter (LD)]

My Lords, I hope the Minister will see that these amendments in the name of the noble Baroness, Lady Hayman of Ullock, are helpful because they give expression to what he said in Committee: that the Government will move forward on a step-by-step basis.

Why do I think that is important? First, again in Committee, the Minister made it absolutely clear that there were no institutions or research bodies—nobody—making a claim that they wanted to do any form of gene editing on anything other than farm animals, and that the only reason why animals beyond farm animals were in the Bill was, to quote the Minister, to “future-proof the Bill”. That is fine, but let us give expression to that future-proofing by ensuring that there is a degree of phasing.

Secondly—this is the point that the noble Baroness, Lady McIntosh, touched on—the consultation that the Government did on the statutory instrument in advance of this Bill indicated that there was no support from either consumers or retailers for the sale of animal products into the market. The public appetite is therefore limited. Those of you in this Chamber who are strong proponents of gene editing could very well argue that this phasing amendment would allow time to bring the public along with us.

The third argument, as I think the noble Baroness, Lady Bennett, mentioned, is that while Europe is looking at gene editing, it is not looking at animals at all, and it is a major trading partner. The Welsh have opposed this legislation and, if my timing is correct, the Scottish are voting at this very moment to turn it down as well. Therefore, key partners of ours are moving at a slower pace than ours and therefore there is a strong argument for moving at a measured pace.

However, the strongest argument, which I think will find favour with the noble Lord, Lord Krebs, and others, is for doing this based on the evidence of the science. Yes, we need a proportionate regulatory framework, but we must ensure that we are learning the lessons at every stage and monitoring the adverse effects. We will come to an amendment about this later. Then, going forward, animal welfare is guaranteed, and public benefits are maintained. An argument that allows this in a phased way is the right regulatory approach. If the noble Baroness takes this to a vote, she will have the support of these Benches.

--- Later in debate ---

Moved by

[Baroness Parminter]

22: Leave out Clause 14 and insert the following new Clause—
“Precision bred animal marketing authorisations: reporting obligations(1) Before issuing a precision bred marketing authorisation for the first time, the Secretary of State must establish a monitoring system for the reporting of potential adverse effects on the health or welfare of such animals or their progeny which must enable—(a) the voluntary reporting to the Secretary of State by keepers of animals, animal health and veterinary professionals, or others, of adverse effects,(b) the mandatory reporting to the Secretary of State by the marketing authorisation holder of adverse effects, and(c) relevant information to be available to support future research.(2) Regulations under subsection (1) may—(a) define what is meant by adverse effects on health and welfare,(b) prescribe information to be required from the notifier for reporting adverse effects to the Secretary of State,(c) make provision for requiring the recipient of marketing authorisation to take prescribed steps, in connection with supplying such an animal to another person, to secure that prescribed information about the subsequent health and welfare of that animal or its progeny, is provided by, or can be collected from that other person, and(d) determine the period after marketing authorisation that such reporting of adverse effects on the health and welfare of animals or their progeny of a given precision bred technique is to be required.(3) Regulations under this section are subject to the affirmative procedure.”Member’s explanatory statement
This amendment requires that, before precision bred animals are marketed, there be mechanisms established for reporting possible adverse effects on the animals’ health and welfare or that of their progeny. Regulations shall define adverse effects, details of the information required, and the time period over which it is required for any given precision breeding technique and application.

[Baroness Parminter (LD)]

My Lords, Amendments 22 and 23 are in my name and that of the noble Lord, Lord Trees. My name is at the head, but they are really joint amendments, and we grateful for the support of the noble Baroness, Lady Hayman, on the Labour Front Bench and my noble friend Lady Bakewell of Hardington Mandeville from the Liberal Democrats. The aim of the amendments is to ensure that a very clear monitoring system is set up in advance of when gene-edited animals are marketed. This is to ensure that the lessons can be learned about any adverse, or indeed positive, effects on animal welfare so that, throughout the process, we can make those learnings available to others so that animals can benefit in the future.

The provisions in Clause 14, which we are proposing this amendment as a replacement for, say that the Government “may” do this—but this is a fundamental issue about whether or not we are ensuring that a proper surveillance and monitoring system is in place right from the beginning. We would certainly concede that it is appropriate that the regulations to implement such a provision were in secondary legislation, but that is not what Clause 14 says: it basically says that the principle of undertaking a monitoring system is only a “may”, not a “must”. As was referred to earlier this evening, in comparable legislation—the Human Fertilisation and Embryology Act—the principle of having a surveillance and monitoring system in the Act and the regulations for how to deliver it are in secondary legislation. This seems to be a reasonable position.

The Minister talked on a number of occasions this evening about the research project with a Scottish university on how these regulations might work in practice. If you have the provisions on how they will be delivered in secondary legislation, that seems to be appropriate. But our amendment would put in the Bill a provision that the Government will introduce a surveillance and monitoring system and that the information will be recorded and available to inform decisions in the future to guarantee animal welfare— which is a common theme that we have covered this evening.

I am grateful to the Minister and the Bill team for their meetings with me, the noble Lord, Lord Trees, and others on this matter between Committee and Report. I do not wish to put words into the Minister’s mouth, but I can guess what he will say in response to our amendment, given the email that the noble Lord, Lord Trees, and I received from the Bill team on 13 January. The objections were that what was in the Bill was proportionate and what we were asking for was not a proportionate form of regulation. The exact words were that our amendment

“could be seen as being too burdensome a requirement for industry and would remove our ability to scale back reporting requirements in the future if we have a scientific basis for doing so”.

To be clear, our amendment is about putting in the Bill a requirement that there is scientific monitoring; we are not saying that the regulations need to go in the Bill. But the Bill team basically says that making it effectively something that the Government must do— putting it in the Bill—is too “burdensome” a requirement for industry. That does not seem a proportionate approach to a regulatory process, where you are balancing the rightful requirements of people going into this new industry against public benefit and animal welfare. This gets the scales wrong.

This is compounded when the email goes on to say:

“Introducing a requirement on the face of the bill to require and publish data from clinical outcomes from research would also curtail our flexibility and could lead to issues with commercial sensitivity”.


Again, it is not beyond the wit of man for Governments to produce regulations in secondary legislation that ensure that legitimate issues of commercial sensitivity are handled—but that should not preclude the duty on companies to supply that information so that lessons can be learned for the benefit of both animal welfare and public confidence, which is an issue that I think the noble Lord, Lord Trees, will address in some detail.

So I look forward to what other noble Lords will say and how the Minister will respond to both our amendments. I reserve our position on moving to a vote. But we think that this is a really important way of doing what the Government say they want to do: move ahead with this in a step-by-step way, while ensuring that the evidence is retained from the relevant companies and available to inform future research.

--- Later in debate ---

I hope that, in the light of these points, I can persuade the noble Baroness and the noble Lord to consider not pressing their amendments.

[Baroness Parminter (LD)]

I thank the Minister for that reply. Sadly, it is quite clear, in the almost immortal words of the noble Lord, Lord Cameron, this evening, that we have not yet managed to make a dent in the Government’s protective carapace on this Bill—it is a great phrase—which is a disappointment, as a number of other amendments earlier in the evening led up to this amendment.

I do not want to spend much time. I just want to make two points to the Minister. He did not answer the fundamental question that Clause 14 says only that regulations “may” make provision. There is absolutely nothing to stop a future Government—and I do not wish to impugn the Minister’s character or motives—not doing anything at all. It is not about the regulations in future; they do not need to introduce a surveillance monitoring system in the future because all that is in the Bill is that regulations “may” make provision. If it was regulations “must” make provision, that might have made a difference, but the Minster was not prepared to concede that.

Secondly, we have a difference of opinion on the issue of commercial sensitivity. I referred to other legislation in comparable fields of human research where this issue has been overcome, and the noble Lord, Lord Trees, outlined other legislation in the veterinary field where this commercial sensitivity issue has been addressed with wording in legislation to that effect.

So I am not content with what the Minister has said. I have seen where we have been heading this evening, but I think it is a matter of principle. For those of us who feel strongly about this, this was a solid amendment seeking to do a good job to help this Bill from both sides of the House, and I wish to press it to a vote.